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An elevated serum level of NM23-H1 protein is a poor prognostic factor in patients with various hematologic malignancies.
The extracellular NM23-H1 protein promotes the in vitro growth and survival of acute myelogenous leukemia (AML) cells and
inverselyinhibits theinvitrosurvival of normal peripheral blood monocytes in primary cultureat concentrations equivalent to the
levels found in the serum of AML patients. The growth and survival promoting activity to AML cells is associated with cytokine
production and activation of mitogen-activated protein kinases (MAPKs) and signal transducers and activators of transcription
(STAT) signaling pathways. Inhibitors speciﬁc for MAPK signaling pathways inhibit the growth/survival-promoting activity of
NM23-H1. These ﬁndings indicate a novel biological action of extracellular NM23-H1 and its association with poor prognosis.
These results suggest an important role of extracellular NM23-H1 in the malignant progression of leukemia and a potential
therapeutic target for these malignancies.
1. NM23 Expressionand
Hematologic Malignancies
T h eN M 2 3g e n ew a si d e n t i ﬁ e db yd i ﬀerential hybridization
of a cDNA library with total RNA extracted from slightly and
highly metastatic melanoma cell lines [1]. The NM23 gene
has been identiﬁed as a family of genes encoding diﬀerent
isoforms of nucleoside diphosphate kinase (NDPK) [2].
NM23 genes play critical roles in cellular proliferation, dif-
ferentiation, oncogenesis, and tumor metastasis, and the
mechanisms of these pleiotropic eﬀects are not well under-
stood[3,4].TenisotypesofthehumanNM23genehavebeen
identiﬁed [5]. Among these, only NM23-H1 and NM23-
H2 have been studied extensively in human cancers. The
level of NM23-H1 expression is inversely correlated with
the tumor’s metastatic potential in experimental rodent
cells and in human tumors, such as breast, ovarian, cer-
vical, and gastric cancer, hepatocellular carcinoma, and
melanomas [4]. Exogenous overexpression of NM23-H1
reduces the metastatic potential of multiple types of cancer
cells and suppresses in vitro tumor cell motility and invasion
[6]; therefore, NM23-H1 is implicated in the regulation of
metastasis in a variety of human cancers, and its overex-
pression predicts a favorable patient prognosis. In contrast,
elevated NM23-H1 expression is related to a more aggressive
disease in neuroblastoma and many hematologic malignan-
cies [7–11]. The signiﬁcance of NM23-H1 overexpression
as a prognostic factor is dependent on tumor cell types
although the mechanism of this discrepancy is unknown.
We previouslyreported thatanondiﬀerentiating myeloid
leukemia cell line produced diﬀerentiation-inhibiting factors
[12, 13]. We puriﬁed one of these factors as a homologue
of mouse NM23-M2 [14]. The NM23-H1 gene was overex-
pressed in various hematologic neoplasms, including AML,
acute lymphoblastic leukemia (ALL), chronic myelogenous
leukemia in blastic crisis (CML-BC), and myelodysplas-
tic syndrome (MDS), more than in normal blood cells
(Figure 1(a))[ 10]. The progression of CML was accompa-
nied by the overexpression of NM23-H1 mRNA [15]. This
increaseinNM23-H1wasobservednotonlyinleukemia,but
also in malignant lymphoma. It has been reported that high-
grade non-Hodgkin’s lymphoma and Hodgkin’s lymphoma2 Advances in Hematology
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Figure 1: Clinical signiﬁcance of NM23-H1 expression in hematologic malignancies. (a) Overexpression of NM23-H1 gene in hematologic
malignancies [10, 20, 31]. Quantitative RT-PCR analysis on NM23-H1 mRNA in human bone marrow mononuclear cells (BM-MNC) in
normal (n = 5), AML (n = 110), acute lymphoblastic leukemia (ALL, n = 9), and chronic myelogenous leukemia in the chronic phase
(CML-CP, n = 9), CML in blast crisis (CML-BC, n = 7), myelodysplastic syndrome (MDS, n = 9), MDS overt leukemia (n = 5). The
mRNA levels were normalized for gapdh mRNA. The positive control (the index = 100) is represented by RNA extracted from the human
leukemia cell line (HEL). Mann-Whitney’s U test (versus normal). ∗P<0.05, ∗∗P<0.001. (b) Overall survival curves of patients with AML,
according to NM23-H1 expression level [31]. High NM23-H1 (>100 index) patients (n = 32, solid line) had a worse prognosis than low
NM23-H1 (≤100) patients (n = 71, broken line).
exhibited signiﬁcantly higher levels of NM23-H1 expression
than low-grade non-Hodgkin’s lymphoma [16–19]. NM23-
H1genewasoverexpressedinAMLcells,andahigherlevelof
NM23-H1 expression was correlated with a poor prognosis
in AML (Figure 1(b))[ 10, 20, 21]. Multivariate analysis of
putative prognostic factors revealed that elevated NM23-H1
mRNA levels signiﬁcantly contributed to the prognosis of
patientswithAML[10].NM23-H1andNM23-H2arehighly
expressed in normal CD34+ hematopoietic progenitors but
are downregulated during normal hemopoietic maturation
[22]. These genes are also downregulated during in vitro
diﬀerentiation of AML line cells [23, 24]. These ﬁndings
suggest an important role for NM23-H1 and NM23-H2 in
controlling hemopoietic diﬀerentiation and leukemic pro-
gression [22–24]. Taken together, these results indicate that
the expression of NM23 is downregulated during hem-
atopoietic maturation, and its overexpression is found in
manyhematologicmalignanciesandpredictspoortreatment
outcome of patients with AML (Figure 1).
2.ClinicalSigniﬁcanceof
ExtracellularNM23-H1 Proteinin
Hematologic Malignancies
NM23 has no secretion signal peptide but is nonetheless
detected in conditioned medium of some tumor cell lines
and in body ﬂuids [14, 25–28]. The mechanisms by which
NM23-H1 protein is secreted into the extracellular environ-
ment are unclear. Recently, Keller et al. [29] showed a new
pathway for the secretion of many inﬂammatory response
proteins without signal sequences. This unconventional
secretion required the catalytic activity of caspase-1 and
could rapidly release a wide variety of proteins involved inAdvances in Hematology 3
triggerdetoxiﬁcation,tissuerepair,andcellsurvival.Further-
more, an exosome-associated export pathway of a number of
proteins without signal sequences from the cells is reported
[30]. It would be interesting to examine whether these new
secretion pathways secrete NM23 protein; however, unlike
secretion, it might be the release of NM23 protein by dying
tumor cells overexpressing NM23.
We determined the serum level of NM23-H1 protein by
enzyme-linked immunosorbent assay (ELISA) and assessed
the association between this level and the clinical outcome
of patients with hematologic malignancies [17, 25, 31, 32].
As shown in Figure 2(a), serum NM23-H1 levels were
signiﬁcantly higher in all of these hematologic malignancies
u s e dt h a ni nan o rm a lc o n tr o l[ 31, 32]. The 102 patients with
AML were divided into two groups with diﬀerent serum
NM23-H1 levels, to compare the overall survival of the two
groups. All the patients with levels higher than 80ng/mL
died within 2 years. The 2-year survival rates for the high-
NM23-H1 (≥80, n = 29) and low-NM23-H1 (<80, n = 73)
groups were 0% and 33.3%, respectively (Figure 2(b)). The
univariate analysis showed that unfavorable prognostic
factors for overall survival were WBC count over 50,000/μL,
LDH level over 5× normal, and NM23-H1 protein level over
80ng/mL. Multivariate analysis using Cox’s proportional
hazard model showed that serum NM23-H1 level (≥80ng/
mL) was the strongest unfavorable factor, followed by WBC
count and LDH. Thus, the elevated serum NM23-H1 levels
signiﬁcantly contributed to the prognosis of AML patients
[32]. The 149 patients with aggressive (intermediate- and
high-grade) non-Hodgkin’s lymphoma were divided into
groups with diﬀerent NM23-H1 levels at a cutoﬀ value
of 80ng/mL. The 3-year survival rates for the high (≥80,
n = 28) and low NM23-H1 groups (<80, n = 121) were 6.7
and 76.4%, respectively (Figure 2(c)). These results suggest
that an elevated serum NM23-H1 concentration predicts
a poor outcome of aggressive non-Hodgkin’s lymphoma
[25]. The prognostic ability of serum NM23-H1 protein was
conﬁrmed by examining a number of patients with various
types of malignant lymphoma in our study involving a
number of diﬀerent institutions and numerous case studies
[11, 17–19, 32].
Extracellular NM23 proteins have been reported in the
conditioned medium of some tumor cell lines, in body
ﬂuids, and on the cell surface in tumor cell lines [14, 22, 26–
28, 35, 36]. High concentrations of NM23 protein are
found in the serum and body ﬂuid of patients with tumors
overexpressingNM23,anditisstronglysuggestedthatserum
NM23 protein is derived from tumor cells [18, 31, 32]. Once
again serum NM23-H1 levels were signiﬁcantly higher
in patients with all hematologic malignancies tested than
in normal/healthy controls (Figure 2(a)), and an elevated
serum NM23-H1 protein concentration predicted a poor
outcome of AML (Figure 2(b)) and various types of
malignant lymphoma (Figure 2(c)) [11, 17–19, 32]. These
results suggest that extracellular levels of NM23-H1 play an
important role in clinical outcome in patients with AML and
malignant lymphomas.
3.Biological FunctionsofExtracellular
NM23-H1 Protein
The mechanisms by which NM23-H1 protein is secreted
into the extracellular environment and aﬀects the outcome
of patients are unclear. Very little information is available
concerning extracellular expression and function although
many studies have examined the expression of intracellu-
lar NM23 proteins; therefore, we focused on extracellular
NM23-H1 protein derived from tumor cells, because its
clinical signiﬁcance is higher than that of intracellular
overexpression [31], and the elevated extracellular expres-
sion of NM23-H1 has not been found in normal healthy
plasma [25]. To demonstrate the clinical importance of
extracellular NM23-H1 protein as a therapeutic target of
patients with hematologic malignancies, we surveyed the
biological functions of extracellular NM23-H1 protein. First,
we investigated the extracellular functions of recombinant
NM23 (rNH23) proteins on the survival and growth of
normal and leukemic PBMNC and their association with the
poor prognosis of AML patients.
3.1. Eﬀect of Extracellular NM23 Protein on the In Vitro
Growth/Survival of Primary Cultured AML Cells. To inves-
tigate the potential pathological link between the elevated
serum level of this protein and poor prognosis, we examined
the extracellular functions of rNM23 protein on the in vitro
growth/survival of primary cultured AML cells. rNM23-H1
protein promoted the in vitro growth/survival of AML cells
at concentrations equivalent to the levels found in AML
patients. This ﬁnding indicates a novel extracellular function
of NM23-H1 and its potential link with poor prognosis
(Figure 3). Both rNM23-H1 and rNM23-H2 promoted the
growth/survival of AML cells; therefore, this activity of
rNM23 is independent of H1/H2 isotypes. The mutant
NM23-H1His protein, which does not have any NDPK activ-
ity, also promoted the growth/survival of AML cells. These
results indicate that the activity of NM23 is independent
of its NDPK activity [33]. How extracellular NM23-H1
protein promotes the growth/survival of AML cells remains
unclear. We examined cytokine levels in the conditioned
medium (CM) of AML cells treated with or without rNM23-
H1, using cytokine antibody array and ELISA. Various
cytokines and chemokines were detected in 48h CM of
AML cells growth/survival promoted by rNM23-H1 [33].
These cytokines included TNFα,I L - 1 β, IL-6, IL-8, I-309, IL-
10, GM-CSF, and RANTES. The cytokine-inducing activity
of rNM23-H1 was associated with its growth/survival-
promoting activity for AML cells. Although the patterns
of cytokine induction are diﬀerent among cases, cytokines
knownasagrowthfactorforAMLcells,suchasGM-CSFand
IL-1β, were induced in CM of NM23-sensitive cases but not
NM23-unresponsive cases. Moreover, the induced-cytokine
concentrations reached physiologically eﬀective levels. To
investigate the correlation between cytokine-inducing activ-
ity and the growth/survival-promoting activity of rNM23-
H1,wetriedtoinhibitthecytokinesusingspeciﬁcantibodies
(anti-TNFα, anti-IL-1β, and anti-IL-6 antibodies). All these
antibodies alone or some combinations tested partially4 Advances in Hematology
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Figure 2:ClinicalsigniﬁcanceofextracellularNM23-H1proteininhematologicmalignancies.(a)SerumNM23-H1proteinlevelsinnormal
healthy control and hematologic malignancies [31]. Normal control (n = 21), AML (n = 102), ALL (n = 6), CML-CP (n = 13), CML-BC
(n = 9), and MDS (n = 12), MDS overt leukemia (n = 6). Mann-Whitney’s U test versus control, ∗∗P<0.001. (b) Overall survival curves of
patients with AML [32]. High-NM23-H1 (≥80ng/mL) patients (n = 29) had a worse prognosis than low-NM23-H1(<80ng/mL) patients
(n = 73). (c) Overall survival curves of patients with intermediate and high-grade non-Hodgkin’s lymphoma [11, 25]. High-NM23-H1
(>80ng/mL) patients (n = 28) had a worse prognosis than low-NM23-H1(<80ng/mL) patients (n = 121).
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inhibited the rNM23-H1-induced growth/survival of AML
cells. Anti-GM-CSF antibody also inhibited both GM-CSF-
induced and rNM23-induced growth/survival of AML cells.
These results suggest that the growth/survival-promoting
activity of this protein may be partly mediated by the
induction of these cytokines (Figure 3). We next investigated
the NM23-induced-signal transduction pathways relating
with cell proliferation, survival, and cytokine production,
namely, MAPK (p38, Erk1/2, JNK), STAT, AKT/PI3K, and
NFκB in AML cells. Of these pathways, extracellular rNM23-
H1 activated MAPK (p38, Erk1/2) and STAT, but not others
[33]. STATs are known as key proteins playing roles as
signal messenger and transcription factors that participate
in normal cellular responses to cytokines. The constitutive
activation of STAT3 has been reported to be associated
with a wide variety of human malignancies containing
AML. rNM23-H1 increased the total amount of STAT1
protein and the phosphorylation of Tyr and Ser. STAT3
was phosphorylated on Tyr705 in the absence of rNM23-
H1, but Ser727 of STAT3 was also phosphorylated in the
presence of rNM23-H1. Ser phosphorylation of STAT3 has
been reported to be required for maximal transcriptional
activity [37]. STAT5 (Tyr694) was also activated by rNM23-
H1 [33]. The individual signaling pathways induced by
rNM23-H1 protein were blocked in AML cells using speciﬁc
pharmacologicalinhibitors,SB202190andSKF86002forp38
MAPK, PD98059 for extracellular signaling kinase (ERK,
also known as MEK), and Curcumin for STAT3 [38]. These
inhibitors suppressed the rNM23-induced growth/survival
promotion of AML cells [33]. These ﬁndings indicate that
the activity of rNM23-H1 is associated with the activation
of these signaling pathways in AML cells [33]. MAPK/STAT
activation by conventional growth factors takes only a few
minutes; however, the activation of these signaling pathways
by rNM23-H1 required a longer time than various mitogens
[33, 39]; therefore, it might be an indirect activation rather
than a direct activation by NM23 molecules. Taken together,
these observations suggest that extracellular NM23-H1 may
play an important role in the malignant progression of
leukemia, and the inhibitors of extracellular NM23-H1
protein or inhibitors for the signaling pathways activated
by extracellular NM23-H1 should be evaluated for their
potential treatment as an approach to these malignancies
(Figure 3).
Lilly and his colleagues reported heterogeneity in the
ability of AML samples to bind and respond to extra-
cellular NM23-H1 [40]. The authors oﬀered evidence
that binding was essential for support survival. Although
rNM23-H1 promoted the survival of the most primitive
blasts within responding AMLs, it was not these cells that
actually bound the protein. Instead, rNM23-H1 bound to
more mature CD34low/CD34− and CD11b+ cells, showing
an indirect survival beneﬁt of rNM23-H1 on primitive
blasts. Collectively, these results show that NM23-H1 pref-
erentially binds to the more mature cells of the AML
clone that are CD34low/CD11b+. However, the survival of
both the more mature (CD34low/wCD11b+) and immature
(CD34+/CD11b−) cells is enhanced. In support of this
ﬁnding, the survival of puriﬁed blast cells was enhanced by
conditioned medium (CM) of more mature cells from the
clone that had been stimulated by rNm23-H1. Levels of IL-
1β and IL-6 in rNM23-H1 CM mirrored the potency of
the CM to promote blast cell survival. These data indicate
that NM23-H1 indirect survival aﬀects the CD34+/CD11b−
cells, by inducing supportive cytokine release from the more
mature CD34low/CD11b+ cells. The authors oﬀered the ﬁrst
evidence of novel crosstalk between cell populations within
the tumor (AML) clone. Moreover, these ﬁndings have
implications for the role of NM23-H1 in AML and its use
as a prognostic marker, well coinciding with our results
(Figure 3).
3.2. Eﬀect of Extracellular NM23 Protein on the In Vitro
Growth/Survival of Primary Cultured Normal Peripheral
Blood Mononuclear Cells (PBMNCs). We examined the
extracellular eﬀects of rNM23-H1 protein on the in vitro
survival of primary cultured normal PBMNC. rNM23-
H1 inhibited the survival of PBMNC at concentrations
equivalent to the levels found in the serum of AML patients
[34]. The rNM23 responsible adherent cells were CD68-
positive and nonspeciﬁc-esterase- (NSE-) positive mono-
cytes. On the other hand, rNM23 did not inhibit, rather
slightly stimulated, the survival of nonadherent PBMNC
(mainly CD3-positive lymphocytes). These results indicate
that extracellular rNM23-H1 protein aﬀects the in vitro
survival of normal immune cells, such as monocytes. The
inhibitoryeﬀectofthisproteinonnormalmonocytesmaybe
associatedwiththepoorprognosisofhematologicmalignan-
cies, since monocytes/macrophages also play a crucial role in
the immune system.
Moreover, rNM23-H1 protein promoted the production
of various cytokines and chemokines, including proin-
ﬂammatory cytokines in normal PBMNC, especially in
monocytes [34]. By using a human cytokine array system,
we analyzed NM23-regulated cytokines in CM of PBMNC
treated with rNM23-H1. Cytokine arrays showed that the
expressions of inﬂammatory cytokines (IL-1β,I L - 6 ,I L -
8, GM-CSF, and MCP-1) were signiﬁcantly induced in
CM of rNM23-H1-treated cells. It has been known that
inﬂammation is an important component of the tumor
microenvironment although the mechanisms through which
immune cells might promote tumorigenesis are unclear
[41]. Some cytokines induced by rNM23-H1 such as GM-
CSF and IL-1β, practically and directly promoted the
growth/survival of primary cultured AML cells (Figure 3).
The cytokine arrays also showed that rNM23-H1 enhances
theproductionofMCP-1andIL-10bynormalPBMNC[34].
It has been described that MCP-1 increases recruitment of
tumor-associated macrophages (TAMs), leading to a higher
degree of angiogenesis [42]. TAMs generally express an M2-
like phenotype [43], which is characterized by high IL-10
expression and low tumoricidal activity and promotes tissue
remodeling and angiogenesis [41]. Buxton et al. reported
the angiogenesis-promoting activity of extracellular NM23
p r o t e i ni nb r e a s tc a n c e r[ 44]. In most human tumors, TAM
inﬁltration is associated with poor prognosis, as seen in
Hodgkin’s disease [45]. Collectively, these results indicate
that NM23 protein in extracellular environment activates6 Advances in Hematology
monocytes and induces the tumor-promoting inﬂammatory
cytokines and the immunosuppressive cytokines in normal
PBMNC. These results also show that extracellular NM23-
H1 could oﬀer tumor cells an environmental condition
convenient for their growth/survival through the cytokine
production of normal PBMNC, which in turn might con-
tribute to the poor outcome of patients with elevated serum
levels of NM23-H1 protein (Figure 3).
Although rNM23-H1 induced various cytokines in both
normal and leukemic PBMNCs, it promoted only the
growth/survival of AML cells but not normal PBMNCs
and rather stimulated its apoptosis. Moreover, rNM23-H1
protein did not have any eﬀects on the growth/survival of
normal endothelial cells (HUVECs) and various tumor cell
lines (leukemia, lymphoma, neuroblastoma, and lung) [34].
NM23 proteins promoted the induction of various cytokines
in the normal monocytes but not in monocytic leukemia cell
lines (THP-1 and U937). Therefore, the survival-inhibiting
activity of rNM23 might be speciﬁc for normal monocytes.
These results indicated that rNM23 induced TAM-like
functions but did not increase the growth and survival of
normal monocytes, in contrast to AML cells. Taken together,
these observations suggest that extracellular NM23-H1 may
play an important role in the malignant progression of
leukemia through normal monocytes (Figure 3).
3.3. Eﬀects of Extracellular NM23 Protein on the In Vitro
Growth/Survival and Diﬀerentiation of Other Hematopoi-
etic Cells. Willems et al. [22] previously reported that
NDPK/NM23waspresentinnormalhumanplasmaandthat
NDPK activity correlated with hemoglobin levels, indicating
the presence of NM23 in plasma as a consequence of
red blood cell lysis. Moreover, they reported a modulating
eﬀect of extracellular NM23 proteins on the terminal stages
(CD34+CD38+ progenitor cells) of normal hematopoietic
diﬀerentiation [46]. More erythroid burst-forming units
(BFU-E) and fewer macrophage colonies (CFU-M) were
observed in cultures containing any of the NM23 isoforms
examined, even the enzymatically inactive H118N mutant
of NM23-H1. They suggest that fairly high concentrations
of NM23 constitutively present in plasma/serum could
have a physiologic role in supporting erythropoiesis and
inhibiting excessive macrophage formation. It is interesting
that extracellular NM23 serves as an alarm molecule for
informing on red blood cell lysis and as a supporting
molecule for normal erythropoiesis. We also reported that
extracellular NM23 could inhibit the erythroid diﬀeren-
tiation of human leukemia cell lines (K562, HEL, and
KU812) without any eﬀect on proliferation [47] and that
serum NM23-H1 levels in AML-M6 (acute erythroleukemia
classiﬁed by FAB (French-American-British) classiﬁcation)
were especially high and signiﬁcantly higher than that in
otherFABsubtypesofAML[32].Theelevatedlevelsofextra-
cellular NM23 in AML-M6 might function as proliferation-
supporting molecules of erythroleukemia cells as in normal
erythropoiesis. In contrast to erythropoiesis, extracellular
NM23-H1 seems to be inhibitory to the growth/survival
of normal monocyte lineage cells [46]; however, it could
promote the growth/survival of primary cultured AML-M5
(acute monocytic leukemia classiﬁed by FAB classiﬁcation)
cells [33]. Serum NM23-H1 levels in AML-M5 were higher
than that in the other FAB subtypes of AML except AML-
M6 [32]. Taken together, these results suggest that an
elevated serum level of NM23-H1 protein in AML aﬀects
the biological properties of normal hematopoietic cells and
leukemia cells of speciﬁc lineages and speciﬁc diﬀerentiation
stages and causes poor prognosis.
4.ExtracellularNM23-H1 ProteinasaPotential
Prognosticand Therapeutic Target for AML
Recent advances in genome technologies and the ensu-
ing outpouring genomic information-related cancer have
accelerated the conversion from a genome discovery into a
tangible clinical endpoint. Successful examples of translating
cancer genomics into therapeutics and diagnostics show the
importance of establishing the biological relevance of a can-
cer genomic discovery in realizing its clinical potential [48].
NM23-H1 plays complex roles in the development of diverse
cancers including carcinoma, high-grade lymphomas, and
AML. As has been mentioned, in the case of AML and
lymphomas, serum NM23-H1 protein is elevated with
highest levels correlating with poorest prognosis. Moreover,
the data of Lilly and colleagues [40] and our recent studies
[33,34]stronglyindicatethatextracellularNM23-H1canact
asatumor-derivedgrowth/survivalfactorinAML(Figure 3).
These ﬁndings suggest an important biological role of
extracellular NM23-H1 in the malignant progression/poor
prognosis of leukemia and a potential therapeutic target for
these malignancies.
As shown in Figure 3, extracellular NM23-H1 derived
from tumor (AML) cells generates a supportive microen-
vironment convenient for their growth/survival of primary
AML cell through cytokine production of AML cells and
normal PBMNC; therefore, the reduction of extracellular
NM23-H1 protein concentration or inhibitors of its action
shouldbeevaluatedfortherapeuticpotentialtocombatthese
malignancies. Although it might be a useful technique to
reduce the serum level of this protein using therapeutic
ﬁltration devices such as Hemopuriﬁer that selectively target
the removal of immunosuppressive proteins from the entire
circulatory system [49], it will be very important to reveal
the signal transduction pathways induced by extracellular
NM23-H1 protein to increase growth/survival of AML cells.
4.1. NM23 Receptors. Lilly et al. [40] recently reported the
heterogeneity in the ability of AML samples to bind and
respond to extracellular NM23-H1 and oﬀered evidence
that binding was essential for improveing survival. These
data imply that some AMLs express an NM23-H1 receptor
whereas others do not. It is interesting to examine the
receptor molecules for extracellular NM23-H1 on AML
cells. Recent evidence suggests that NM23-H1 can bind
to a cleaved form of Mucin1 called MUC1∗,w h i c hi s
present on the surface of many cancer cell lines and on
pluripotent stem cells [50, 51]. The binding of NM23-
H1 to MUC1∗ was reported to result in dimerization of
MUC1∗, and subsequent activation of the MAPK pathwayAdvances in Hematology 7
to increase proliferation of the breast cancer cell line T47D
[50]. Although these studies indicate that MUC1∗ can act
as a receptor for NM23-H1, Lilly et al. [40] showed that
cell surface binding to AML cells is independent of MUC1∗,
and therefore an alternative receptor must be present on
thesecells.Furtherstudiesshouldinvestigatetherelationship
between NM23-H1 binding and responses to AML therapies
and aim to determine the nature of the NM23-H1 receptor
in AML, which may provide a novel target for adjunctive
therapies.
Apetoh et al. [52] identiﬁed Toll-like receptor 4 (TLR4)
ligand, high-mobility group box 1 (HMGB1) alarmin pro-
tein from dying tumor cells. This indicated that the molecule
from tumor cells elicits an immune response involving the
induction of inﬂammatory cytokines in a TLR4-dependent
fashion. Reportedly, a number of endogenous proteins bind
and stimulate TLR4: heat-shock protein (HSP) 60, HSP70,
oxidized LDL, surfactant protein A, hyaluronan breakdown
product, ﬁbronectin, and β-defensin-2 [53]. The mechanism
by which extracellular NM23-H1 protein induces various
inﬂammatory cytokines in normal monocytes and AML cells
(Figure 3) is unknown. It will be interesting to determine
whether extracellular NM23 binds and stimulates TLR4-like
HMGB1.
4.2. Small Molecules Regulating NM23 Functions. The
downstream signaling pathway induced by the extracel-
lular NM23-H1 also would be a potential therapeutic
target for AML. We previously reported that inhibitors
of MAPK/STAT3 activity suppressed the NM23-induced
growth/survival of AML cells [33]. Various inhibitors are
now under development, since MAPK and STAT3 signaling
activations and tumor-induced inﬂammatory conditions are
widely observed in malignant progression [54–57]. These
agents might have potential to improve treatment for
AML patients with a poor treatment outcome predicted by
measuring serum levels of NM23-H1.
NM23 has a large number of functions, including NDPK
activity [1, 58, 59], a transcription factor PuF for the c-Myc
promoter [60], and protein kinase activity [61, 62]. Coin-
cident with these biological characterizations, the NM23
proteinsarepostulatedtoparticipateinmultiplebiochemical
activities and associations. However, it is unknown how
one small molecule like NM23 exerts these many functions.
Nm23-H1 and H2 form homo- and heterohexamers. It may
allow the formation of a variety of isoenzymes with subtly
diﬀerent functions. Moreover, NM23 proteins have been
reported to be associated with other proteins; transcription
factors such as the retinoic acid receptor-related orphan
receptor a and the retinoic Z receptor b [63], the heat
shock protein Hsc70 [64], telomeres [65], Epstein-Barr virus
(EBV) nuclear protein EBNA-3C [66], prune [67], and
a low-molecular-weight GTPase Rad [68, 69]. These pro-
tein:proteininteractionsinvolvingNM23proteinmightlight
on studies of the multifunction observed in NM23 protein.
Although we have not yet had any evidence showing NM23-
interacting proteins in extracellular conditions, development
of small molecules, which can modify the protein:protein
interactions, may provide a novel therapeutic tool to target
malignant AML.
EBV is an oncogenic virus associated with a number
of human malignancies including Burkitt lymphoma and
lymphoproliferative disease. A subset of latent EBV antigens
is required for mediating immortalization of primary B-
lymphocytes. EBNA-3C is one of the six latent proteins
essential for EBV transformation of B-lymphocytes and
interacts speciﬁcally with the NM23-H1 protein. Moreover,
EBNA-3C reverses the ability of NM23-H1 to inhibit
migration of Burkitt lymphoma and breast carcinoma
cells. Therefore, the NM23-H1 is identiﬁed as a cellular
target for EBNA-3C. NM23-H1 is predominantly localized
in the cytoplasm in B-lymphocytes, while NM23-H1 is
predominantly nuclear and colocalized with EBNA-3C in
EBV-transformed B-lymphoblastoid cell lines and in B cells
transfected with EBNA-3C [66]. These results indicate that
EBV may inﬂuence the subcellular localization and function
of NM23-H1 in infected cells. These results also suggest
that it would be important to examine the subcellular
localization of NM23-H1 protein overexpressed in leukemia
and lymphoma. Zhu et al. have reported an interesting small
molecule,named stauprimide, that increases the eﬃciency of
the directed diﬀerentiation of mouse and human embryonic
stem cells (ESCs) in synergy with deﬁned extracellular
signaling cues, such as activin A [70]. Using an aﬃnity-based
approach,NM23-H2wasidentiﬁedasthebiologicaltargetof
stauprimide. By binding to NM23-H2, stauprimide inhibits
NM23-H2 nuclear localization, which, in turn, represses c-
Myc expression, because NM23-H2 in nucleus functions as a
transcription factor for c-Myc [71]. This study points to an
importantroleforstauprimideinmodulatingthesubcellular
localization and function of NM23-H2. The amount of
intracellular NM23-H1 and NM23-H2 is inversely correlated
with diﬀerentiation, and NM23 overexpression is considered
to function as a diﬀerentiation suppressor in AML cells.
Therefore, the suppression of the NM23’s function by
stauprimide should be evaluated for diﬀerentiation inducing
therapy for AML.
Expression of the human isoforms, NM23-H1 and
NM23-H2, is thought to be inversely associated with meta-
static potential of a variety of cancers [72–74]. While NM23-
H1 is strongly associated with metastasis mechanisms in
many tumors, NM23-H2 is not [75–77]. The products of
these two genes, NDPK-A and NDPK-B, were named for
their function as nucleoside diphosphate (NDP) kinases.
NDPK-B is elaborated into the extracellular environment
by the breast carcinoma cell line MDA-MB-435s as well
as other cells derived from solid tumors such as colon,
lung, and prostate [27]. The presence of NDP kinase
activity on the surface and external environment of cancer
cells that exist in the milieu of apoptosis and necrosis
provides eﬀective mechanism for regenerating extracellular
purines. Buxton et al. have shown an attractive evidence
to support secreted extracellular NM23-H2’s (sNDPK-B)
putative role in promoting metastasis [44]. The authors have
provided evidence for a nucleotide-dependent regulation
of angiogenesis by breast cancer of secreted extracellular
NM23-H2 [27, 44, 78–80]. This can be mechanistically8 Advances in Hematology
related to extracellular nucleotide elevation and subsequent
activation of nucleotide receptors to regulate cancer growth
and tumor angiogenesis [44]. These ﬁndings show that
pathologically secreted NM23-H2 and its regulation of
extracellular nucleotides utilize P2Y receptors to stimulate
angiogenesis [44, 78]. These results also represent new
therapeutic targets for antiangiogenic therapies to beneﬁt
patients. Furthermore, the authors have shown a number of
inhibitors for extracellular NDPK-B activity [80]. Catechin
gallates (EGCG, ECG), theaﬂavins, and ellagic acid (EA) are
shown to inhibit NDPK-B completely with the rank order
of potency: EA>theaﬂavins>EGCG>ECG. These compound,
are known to suppress cancer cell proliferation, inhibit
invasion into Matrigel, and inhibit angiogenesis [78, 80]. EA
is a potent NDPK-B inhibitor that may potentiate the sup-
pressionofmetastasisandthusmaybeusefulagentstousein
conjunction with traditional chemotherapy or angiogenesis
inhibitors such as bevacizumab (Avastin). Using EA, we tried
to inhibit the function of NM23/NDPK as a diﬀerentiation
suppressor in AML cells for increasing the eﬃciency of
the directed diﬀerentiation of AML cells in synergy with
all-trans-retinoic acid (ATRA). EA enhanced the ATRA-
induced diﬀerentiation and the apoptosis of human acute
promyelocytic leukemia cell lines [81]. These results might
have implications for the incorporation of anti-NM23 agents
such as EA into therapeutic intervention against leukemia
and possibly other hematologic malignancies overexpressing
NM23.
In conclusion, NM23 has a large number of biological
functions including growth/survival-promoting activity for
AML cells. Inhibitors of NM23 expression and its actions
might hold promise for the treatment of AML. Especially
extracellular NM23-H1 represents an important role in the
malignant progression of leukemia. Therefore, its func-
tional inhibitors and its downstream inhibitors for signaling
pathways activated by extracellular NM23-H1 should be
evaluated for their potential treatment as an approach to
these malignancies.
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